Recent Advances on Ultrasound Contrast Agents for Blood-Brain Barrier Opening with Focused Ultrasound - Archive ouverte HAL
Article Dans Une Revue Pharmaceutics Année : 2020

Recent Advances on Ultrasound Contrast Agents for Blood-Brain Barrier Opening with Focused Ultrasound

Résumé

The blood-brain barrier is the primary obstacle to efficient intracerebral drug delivery. Focused ultrasound, in conjunction with microbubbles, is a targeted and non-invasive way to disrupt the blood-brain barrier. Many commercially available ultrasound contrast agents and agents specifically designed for therapeutic purposes have been investigated in ultrasound-mediated blood-brain barrier opening studies. The new generation of sono-sensitive agents, such as liquid-core droplets, can also potentially disrupt the blood-brain barrier after their ultrasound-induced vaporization. In this review, we describe the different compositions of agents used for ultrasound-mediated blood-brain barrier opening in recent studies, and we discuss the challenges of the past five years related to the optimal formulation of agents.
Fichier principal
Vignette du fichier
Dauba_Pharmaceutics_2020.pdf (2.61 Mo) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03024904 , version 1 (26-11-2020)

Licence

Identifiants

Citer

Ambre Dauba, Anthony Delalande, Hermes Kamimura, Allegra Conti, Benoit Larrat, et al.. Recent Advances on Ultrasound Contrast Agents for Blood-Brain Barrier Opening with Focused Ultrasound. Pharmaceutics, 2020, 12 (11), pp.1125. ⟨10.3390/pharmaceutics12111125⟩. ⟨hal-03024904⟩
114 Consultations
152 Téléchargements

Altmetric

Partager

More